# Bispecific antibodies

Source: https://onco.cc/technologies/bispecific-antibody/  
OnCo record `bispecific-antibody` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A bispecific antibody is one antibody with two different grabbing arms, so it can block two targets at once or pull an immune cell onto a cancer cell.

## Summary

Two families: T-cell engagers (CD3 arm; see separate entry) and dual-target blockers such as amivantamab (EGFR×MET), zanidatamab (HER2 biparatopic), zenocutuzumab (HER2×HER3 for NRG1 fusions), and ivonescimab (PD-1×VEGF), which beat pembrolizumab head-to-head on PFS in NSCLC (HARMONi-2). Bispecifics are also the antibody chassis for the next ADC generation.

## Fields

- Kind: Technology
- Status: approved
- Last checked: 2026-09-04
- Principle: Engineered heavy/light chain pairing (knobs-into-holes, CrossMab, DuoBody) yields one molecule with two specificities.
- Since: 2014
- Strengths: Combination therapy in one molecule; Avidity for co-expressing tumour cells
- Limitations: Manufacturing complexity; Dose finding for two arms

## Notes

- Lymphoma: the CD20 by CD3 bispecifics are the clearest working example of the format. CD3 is not a tumour antigen at all; it is the handle the antibody uses to grip a T cell so that the other arm can hold the tumour, which bypasses the loss of antigen presentation that defeats a checkpoint inhibitor. The price is built into the mechanism: cytokine release syndrome and neurotoxicity are the synapse working, which is why step-up dosing exists.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Bispecific_monoclonal_antibody
- Wikipedia: https://en.wikipedia.org/wiki/Bispecific_monoclonal_antibody

## Connected records

- technologies: [Antibody manufacturing (CHO bioprocessing)](https://onco.cc/technologies/monoclonal-antibody-manufacturing/), [Bispecific ADC](https://onco.cc/technologies/bispecific-adc/), [Downstream purification (Protein A capture, viral clearance, polishing)](https://onco.cc/technologies/downstream-purification-chromatography/), [NK cell engagers](https://onco.cc/technologies/nk-cell-engagers/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/), [Trispecific antibodies](https://onco.cc/technologies/trispecific-antibodies/)
- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [HER2-amplified colorectal cancer](https://onco.cc/cancers/her2-amplified-colorectal/), [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [HIV-associated (AIDS-related) lymphomas](https://onco.cc/cancers/hiv-associated-lymphoma/), [KRAS wild-type pancreatic ductal adenocarcinoma](https://onco.cc/cancers/kras-wild-type-pdac/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [MET exon 14 and MET-amplified non-small-cell lung cancer](https://onco.cc/cancers/met-altered-nsclc/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [PD-L1-high non-small-cell lung cancer without a driver mutation](https://onco.cc/cancers/pdl1-high-nsclc/), [Post-transplant lymphoproliferative disorder (PTLD)](https://onco.cc/cancers/post-transplant-lymphoproliferative-disorder/), [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- targets: [CD137 (4-1BB, TNFRSF9)](https://onco.cc/targets/cd137/), [CD20](https://onco.cc/targets/cd20/), [CD28](https://onco.cc/targets/cd28/), [CD3](https://onco.cc/targets/cd3/), [EpCAM](https://onco.cc/targets/epcam/)
- drugs: [Amivantamab](https://onco.cc/drugs/amivantamab/), [Cadonilimab](https://onco.cc/drugs/cadonilimab/), [Catumaxomab](https://onco.cc/drugs/catumaxomab/), [Ficerafusp alfa](https://onco.cc/drugs/ficerafusp-alfa/), [Iparomlimab and tuvonralimab](https://onco.cc/drugs/iparomlimab-tuvonralimab/), [ISB 2001](https://onco.cc/drugs/isb-2001/), [Ivonescimab](https://onco.cc/drugs/ivonescimab/), [M701](https://onco.cc/drugs/m701/), [Obrixtamig](https://onco.cc/drugs/obrixtamig/), [Petosemtamab](https://onco.cc/drugs/petosemtamab/), [Retlirafusp alfa](https://onco.cc/drugs/retlirafusp-alfa/), [Zanidatamab](https://onco.cc/drugs/zanidatamab/), [Zenocutuzumab](https://onco.cc/drugs/zenocutuzumab/)
- companies: [Amunix Pharmaceuticals](https://onco.cc/companies/amunix-pharmaceuticals/), [Bicara Therapeutics](https://onco.cc/companies/bicara-therapeutics/), [Compass Therapeutics](https://onco.cc/companies/compass-therapeutics/), [Compugen](https://onco.cc/companies/compugen/), [Cullinan Therapeutics](https://onco.cc/companies/cullinan-therapeutics/), [Glenmark Pharmaceuticals (Ichnos Glenmark Innovation)](https://onco.cc/companies/glenmark/), [Harbour BioMed](https://onco.cc/companies/harbour-biomed/), [IGM Biosciences](https://onco.cc/companies/igm-biosciences/), [Janux Therapeutics](https://onco.cc/companies/janux-therapeutics/), [LYSA (The Lymphoma Study Association)](https://onco.cc/companies/lysa/), [Marengo Therapeutics](https://onco.cc/companies/marengo-therapeutics/), [Ranata Therapeutics](https://onco.cc/companies/ranata-therapeutics/), [Wuhan YZY Biopharma](https://onco.cc/companies/wuhan-yzy-biopharma/), [WuXi Biologics](https://onco.cc/companies/wuxi-biologics/), [Xencor](https://onco.cc/companies/xencor/), [Xilio Therapeutics](https://onco.cc/companies/xilio-therapeutics/)
- trials: [A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer](https://onco.cc/trials/nct07102381/), [A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors](https://onco.cc/trials/nct06695845/), [A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma P](https://onco.cc/trials/nct06496178/), [A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.](https://onco.cc/trials/nct07052253/), [A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma](https://onco.cc/trials/nct07023315/), [A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection](https://onco.cc/trials/nct05489289/), [A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer](https://onco.cc/trials/nct06953999/), [A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment o](https://onco.cc/trials/nct06435429/), [A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC](https://onco.cc/trials/nct07807163/), [A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC](https://onco.cc/trials/nct06617416/), [A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer](https://onco.cc/trials/nct05859750/), [A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer](https://onco.cc/trials/nct05235516/), [A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer](https://onco.cc/trials/nct05990127/), [A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepat](https://onco.cc/trials/nct06371157/), [A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemor](https://onco.cc/trials/nct07010263/), [A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07623356/), [A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer](https://onco.cc/trials/nct06385080/), [A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer](https://onco.cc/trials/nct05488314/), [A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy](https://onco.cc/trials/nct06750094/), [A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure](https://onco.cc/trials/nct04988295/), [A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer](https://onco.cc/trials/nct06662786/), [A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07227025/), [A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer](https://onco.cc/trials/nct07276399/), [A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct06667076/), [A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer](https://onco.cc/trials/nct05498428/), [A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer](https://onco.cc/trials/nct05379595/), [A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct03526835/), [A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and Hig](https://onco.cc/trials/nct07412262/), [A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions](https://onco.cc/trials/nct04538664/), [A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer](https://onco.cc/trials/nct05908734/), [A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07535437/), [A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma](https://onco.cc/trials/nct07815665/), [A Study of Ivonescimab in First-Line ES-SCLC](https://onco.cc/trials/nct07245446/), [A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07535463/), [A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC](https://onco.cc/trials/nct07586202/), [A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)](https://onco.cc/trials/nct07602855/), [A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors](https://onco.cc/trials/nct07208773/), [A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)](https://onco.cc/trials/nct02912949/), [A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treat](https://onco.cc/trials/nct03888105/), [A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.](https://onco.cc/trials/nct05944224/), [A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth](https://onco.cc/trials/nct05801029/), [A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer](https://onco.cc/trials/nct04950322/), [A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2](https://onco.cc/trials/nct07203053/), [AALL1331](https://onco.cc/trials/aall1331/), [AK104 for Recurrent or Metastatic Vulvar Cancer](https://onco.cc/trials/nct05932212/), [AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer](https://onco.cc/trials/nct05904379/), [AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer](https://onco.cc/trials/nct06646055/), [AK112 Combined With GAP Conversion Therapy for Locally Advanced Gallbladder Cancer](https://onco.cc/trials/nct07767994/), [AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor](https://onco.cc/trials/nct07158840/), [AMT-116 in Combination With AK112 in Patients With Lung Cancer](https://onco.cc/trials/nct07590531/), [An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer](https://onco.cc/trials/nct06560112/), [Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer](https://onco.cc/trials/nct07635290/), [Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma](https://onco.cc/trials/nct06438822/), [CHRYSALIS](https://onco.cc/trials/chrysalis/), [Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1](https://onco.cc/trials/nct06767514/), [COMPASSION-16 / AK104-303](https://onco.cc/trials/compassion-16/), [ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)](https://onco.cc/trials/nct06951646/), [DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy](https://onco.cc/trials/nct06221748/), [EA2197 ivonescimab: ivonescimab with gemcitabine and cisplatin versus standard chemo-immunotherapy in advanced biliary tract cancer](https://onco.cc/trials/ea2197-ivonescimab/), [Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib](https://onco.cc/trials/nct06120140/), [FORTIFI-HN01](https://onco.cc/trials/fortifi-hn01/), [HARMONi-2](https://onco.cc/trials/harmoni-2/), [HARMONi-3](https://onco.cc/trials/harmoni-3/), [HARMONi-A](https://onco.cc/trials/harmoni-a/), [HERIZON-BTC-01](https://onco.cc/trials/herizon-btc-01/), [HERIZON-BTC-302](https://onco.cc/trials/herizon-btc-302/), [HERIZON-GEA-01](https://onco.cc/trials/herizon-gea-01/), [Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer](https://onco.cc/trials/nct07745296/), [Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC](https://onco.cc/trials/nct07405190/), [Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06928389/), [Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies](https://onco.cc/trials/nct06993025/), [LiGeR-HN1](https://onco.cc/trials/liger-hn1/), [Ligufalimab and Cadonilimab in Advanced Liver Cancers](https://onco.cc/trials/nct06789848/), [MARIPOSA](https://onco.cc/trials/mariposa/), [Mosunetuzumab against rituximab in low tumour burden follicular lymphoma](https://onco.cc/trials/mosun-lbt-fl/), [Mosunetuzumab with lenalidomide in relapsed marginal zone lymphoma](https://onco.cc/trials/mosun-len-mzl/), [Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer](https://onco.cc/trials/nct07412613/), [Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC](https://onco.cc/trials/nct07819591/), [Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets](https://onco.cc/trials/nct07234877/), [Premedication to Reduce Amivantamab Associated Infusion Related Reactions](https://onco.cc/trials/nct05663866/), [Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors](https://onco.cc/trials/nct06814496/), [SAFIR-ABC10](https://onco.cc/trials/safir-abc10/), [SEVILLA](https://onco.cc/trials/sevilla/), [SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer](https://onco.cc/trials/nct05300269/), [Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocri](https://onco.cc/trials/nct07016230/), [Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metast](https://onco.cc/trials/nct07775287/), [Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorecta](https://onco.cc/trials/nct07702032/), [Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors](https://onco.cc/trials/nct07397338/), [Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer](https://onco.cc/trials/nct07637513/), [Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer](https://onco.cc/trials/nct07423585/), [Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody](https://onco.cc/trials/nct06432296/)
- roadmaps: [Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials](https://onco.cc/roadmaps/gallbladder-cancer-roadmap/), [Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting](https://onco.cc/roadmaps/lymphoma-roadmap/)
- terms: [Antibody](https://onco.cc/terms/antibody/), [Antigen escape: how a lymphoma loses the thing the drug was aimed at](https://onco.cc/terms/lymphoma-bio-antigen-escape/), [CD20 bispecific antibodies: step-up dosing, fixed duration and what it is like to take one](https://onco.cc/terms/lymphoma-tx-bispecific-step-up/), [Cytokine release syndrome and ICANS: grading and management](https://onco.cc/terms/lymphoma-tx-crs-icans/), [Fc engineering / effector function](https://onco.cc/terms/fc-effector/), [Immuno-oncology (IO) and checkpoint blockade](https://onco.cc/terms/immuno-oncology/), [Immunoglobulin replacement after CAR-T, bispecifics and long anti-CD20 treatment](https://onco.cc/terms/lymphoma-tx-immunoglobulin-replacement/), [Low antibodies and infection risk for years after anti-CD20 and bispecific antibodies](https://onco.cc/terms/lymphoma-living-infection-years-after/), [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/), [Step-up dosing (T-cell engagers)](https://onco.cc/terms/step-up-dosing/), [What it costs to aim at a lineage antigen](https://onco.cc/terms/lymphoma-bio-lineage-antigen-cost/)
- key papers: [Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL](https://onco.cc/key-papers/paper-aall1731-blinatumomab-children-nejm-2025/), [DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer](https://onco.cc/key-papers/paper-dellphi-301-nejm-2023/), [ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission](https://onco.cc/key-papers/paper-e1910-blinatumomab-mrd-negative-all-nejm-2024/), [EPCORE NHL-1: epcoritamab, a subcutaneous CD20 x CD3 bispecific, in relapsed large B-cell lymphoma including after CAR-T](https://onco.cc/key-papers/paper-epcore-nhl-1-epcoritamab-jco-2023/), [HARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer](https://onco.cc/key-papers/paper-harmoni-2-lancet-2025/), [MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response](https://onco.cc/key-papers/paper-magnetismm-3-elranatamab-natmed-2023/), [MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma](https://onco.cc/key-papers/paper-majestec-1-teclistamab-nejm-2022/), [MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer](https://onco.cc/key-papers/paper-mariposa-nejm-2024/), [Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma](https://onco.cc/key-papers/paper-elm-2-odronextamab-follicular-ann-oncol-2024/)
- ideas: [An open engineering platform for academic ADCs and bispecifics](https://onco.cc/ideas/idea-fund-academic-adc-bispecific-platform/), [Anchor a TGF-beta trap in the tumour stroma so it cannot act everywhere](https://onco.cc/ideas/idea-bio2-tumour-anchored-tgfbeta-trap/), [Antibodies that see mutant KRAS and p53 fragments displayed on the cell surface](https://onco.cc/ideas/idea-bio1-pmhc-bispecifics-public-drivers/), [Bispecific antibodies that engage macrophages instead of T cells](https://onco.cc/ideas/idea-bio2-myeloid-engager-bispecific/), [Fixed-duration, chemotherapy-free first-line treatment for the indolent lymphomas](https://onco.cc/ideas/lymphoma-ev-fixed-duration-chemotherapy-free-first-line/), [Use the brain's own transport door to carry antibody drugs across](https://onco.cc/ideas/idea-bio2-transferrin-shuttle-adc/)
- people: [Ajai Chari](https://onco.cc/people/ajai-chari/), [Catherine Thieblemont](https://onco.cc/people/catherine-thieblemont/), [Elena Garralda](https://onco.cc/people/elena-garralda/), [Michael Dickinson](https://onco.cc/people/michael-dickinson/), [Nai-Kong V. Cheung](https://onco.cc/people/nai-kong-cheung/), [Philippe Moreau](https://onco.cc/people/philippe-moreau/), [Qing Zhou](https://onco.cc/people/qing-zhou/)
- institutions: [American Society of Hematology](https://onco.cc/institutions/ash/), [Chinese Society of Clinical Oncology](https://onco.cc/institutions/csco/), [Comprehensive Cancer Center Mainfranken, University Hospital Würzburg](https://onco.cc/institutions/ccc-wuerzburg/), [European Hematology Association](https://onco.cc/institutions/eha/), [IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola](https://onco.cc/institutions/sant-orsola-bologna/), [IUCT Oncopole (Institut Universitaire du Cancer de Toulouse)](https://onco.cc/institutions/iuct-oncopole/), [National Medical Products Administration / Center for Drug Evaluation](https://onco.cc/institutions/nmpa-cde/), [University Cancer Center Mainz (UCT Mainz) / Universitätsmedizin Mainz](https://onco.cc/institutions/uct-mainz/)
- pathways: [NK-cell recognition: missing self & stress ligands](https://onco.cc/pathways/nk-cell-recognition/), [Receptor tyrosine kinase activation](https://onco.cc/pathways/rtk-activation/)

---
JSON: https://onco.cc/api/v1/entities/bispecific-antibody.json